key: cord-0799305-5bsmx0r7
authors: Chaves Andrade, Marileia; Souza de Faria, Rodolfo; Avelino Mota Nobre, Sergio
title: COVID-19: Can the symptomatic SARS-CoV-2 infection affect the homeostasis of the gut-brain-microbiota axis?
date: 2020-08-24
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110206
sha: 45cd5b6121e05fddb5101bda3fd485ab68f81b2c
doc_id: 799305
cord_uid: 5bsmx0r7

COVID-19 is associated with acute and lethal pneumonia, causing the severe acute respiratory syndrome (SARS), which is not confined to the respiratory tract, as demonstrated by clinical evidence of the involvement of multiple organs, including the central nervous system (CNS). In this context, we hypothesized that both oligosymptomatic and symptomatic patients present an imbalance in the microbiota-gut (immune system) and nervous system axis, worsening the clinical picture. The brain constantly receives a direct and indirect influence from the intestine, more specifically from the immune system and intestinal microbiota. The presence of SARS-CoV-2 in the intestine and CNS, can contribute to both neurological disorders and gut immune system imbalance, events potentialized by an intestinal microbiota dysbiosis, aggravating the patient’s condition and causing more prolonged harmful effects.

The novel Coronavirus 2019 (COVID-19) pandemic, which had the first diagnosed case in Wuhan (China), has different clinical manifestations, ranging from asymptomatic to severe or critical conditions [1] . Worldwide data confirms a higher incidence in elderly patients. For these patients, severe cases cause acute and lethal pneumonia, developing the severe acute respiratory syndrome (SARS). This later is not confined to the respiratory tract, as demonstrated by clinical evidence of the involvement of multiple organs [2] . Based on experimental research, in vitro studies, laboratory analyses from patient's samples, comparative analyses between the SARS and the Middle East respiratory syndrome (MERS) infection, and computational modeling studies, the course of the disease is still being understood and there are gaps regarding the understanding concerning the evolution, pathogenesis and, mainly, therapeutic strategies [3] .

One of these gaps concerns the relationship between SARS-CoV-2 and the nervous system, especially with the brain-gut-microbiota axis. It is now known that a neuroinvasive and neurovirulence profile was demonstrated, in a great number of case reports, in other Coronavirus belonging to the same genetic grouping (Beta Coronavirus), such as the SARS-CoV-1 and the MERS-CoV [4] [5] [6] . During the SARS pandemic of 2002-2003, patients presented neurological complications and in brain tissue specimens' autopsies, SARS-CoV-1 was detected mainly in the cytoplasm of neurons and associated tissue inflammation [7] . It is probable that brain invasion by SARS-CoV-1 occurs via an olfactory route, and is associated with neuronal death as demonstrated in experimental models using mice transgenic for human ACE2 (Angiotensin-converting enzyme). Unlike SARS-CoV (type 1 and 2), MERS-CoV uses a distinct receptor in the cell surface to get access to cytoplasm, named dipeptidyl peptidase 4 receptor (DPP-4), broadly expressed throughout the body on the epithelia, vascular endothelia, and on the brain [7] . It is important to note that in many patients with MERS-CoV infection, was related to neurological complications were observed, ranging from mild to severe clinical manifestations [8, 9] . Since they share genetic, structural, and clinical aspects of the disease, it is likely that many similar mechanisms may apply to SARS-CoV-2. In this respect, an increase in scientific publications suggesting the possibility that the SARS-CoV-2 may affect the central nervous system (CNS) has been observed, with symptoms starting after hospitalization, including 3 headache, disturbed consciousness, and paresthesia as the most frequent of them [10] [11] [12] . It is not known by which pathway the virus accesses the CNS, and it is speculated that it is through retrograde transport through the olfactory nerve and blood pathways infecting endothelial cells or leukocytes [5, 13] .

In addition to the possible direct impacts of the tropism of the virus to the CNS, the homeostatic relationship on the microbiota-intestine and nervous system axis, due to the presence of SARS-CoV-2 in the intestine, can contribute to both neurological disorders and gut immune system imbalance. Since the brain-gut microbiota-immune axis presents bidirectional communication, and microbiota is important for the maintenance of immunological homeostasis and Th17/Treg dynamic balance, which suppress proinflammatory responses throughout the body [14] , an intestinal dysbiosis induced by SARS-CoV-2 may favor a cerebral CNS vulnerability to different injury-causing agents, including the coronavirus itself.

Since SARS-CoV-2 has been observed in feces of patients, adding to the fact that there is evidence of intestinal disorders in 30% of the infected [15], we hypothesize that both oligosymptomatic and symptomatic patients present an imbalance in the microbiota-gut (immune system) and nervous system axis. This results in immediate consequences for symptomatic patients, mainly with regards to the regulation of the inflammatory phase of COVID-19, as well as in oligosymptomatic ones. These changes may have a late repercussion on immunological phenomena, which is crucial to the homeostasis of the body.

Over 95% of the body's entire microbiome (about 100 trillion) resides in the intestine. In turn, the intestine is the largest human immune organ, in continuous contact with the diversity of bacterial products. This microbiome is crucially fundamental for the maturation and maintenance of immunophysiology. The intestinal microbiota is responsible for aiding digestion, synthesizing vitamins, degrading toxins, and forms the 4 microbiome-gut axis. It provides two-way communication ( Figure 1 ) through cytokine, immunological, hormonal, and neuronal signals [16] [17] [18] . Several studies show that the brain constantly receives a direct and indirect influence from the intestine, more specifically from the intestinal microbiota, which modulates neural functions, regulates its health, and reverses disease processes [19] [20] [21] . Bravo and coauthors [19] showed that the administration of L. rhamnosus was able to reduce stress and anxiety/depression behaviors in rodents, whereas in vagotomized animals these benefic effects were not [24, 25] , may affect the homeostasis of the microbiotamucosal immune system's relationship, with repercussions to the CNS, once neuroinflammatory and functional consequence after brain injury are affected by the gut microbiota homeostasis [26] . The real impact of SARS-CoV-2 on the gut microbiota with consequent dysbiosis remains to be defined, but it has become evident that COVID-19 patients with gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain had more severe disease. Still, some of them presented microbial dysbiosis with decreased levels of Lactobacillus and Bifidobacterium [27] . After invading the gut, the virus can reach the CNS through the circulatory pathway or the vagal nerve [28] . Neurological consequences may initially be subjective, such as the above-mentioned headache, disturbed consciousness, and paresthesia [10] , but there 5 may be more severe symptoms (such as depressed level of consciousness, seizure, and stroke) with the course of infection [29] and the inflammatory process, as glial cells and neurons have been reported to express ACE-2 receptors, which intermediates the entry of the virus into cells.

Another key point is related to immunological phenomena that occurs in the intestine.

This contributes to the generation of fundamental regulatory activities for the modulation of local and systemic inflammatory immune responses. It is known that the generation and maintenance of this mucosal immunity are stimulated and maintained by the acquisition of a complex microbiota, with which symbiotic relationships are established [30] .

A breakdown of this dynamic relationship results in chronic inflammatory disorders, including autoimmunity, allergies, and metabolic syndromes and compromises the control of exacerbated immune responses in many diseases [30] . It is known that COVID-19 presents a biphasic course, initially viremic and then uncontrolled inflammation. Therefore, we hypothesize that greater severity of pathogenesis is related to an immune dysregulation added to SARS-CoV-2 gut infection. Therefore, a mucosa proinflammatory response instead of an immune regulation, associated with microbial dysbiosis, may affect the CNS.

In conclusion, it is reasonable to consider this worsening of the clinical picture when the new coronavirus reaches the intestine. This may also cause more severe neurological impairment. Furthermore, the control of the inflammatory process will be even more difficult due to changes in the immune regulation in the intestinal mucosa microenvironment. To the best of our knowledge, there is no publication specifically exploring this hypothesis, but there are data and independent results that support this theory.

COVID-19 diagnosis and management: a comprehensive review

Viral Infections and Their Relationship with Catastrophic Antiphospholipid Syndrome: A Possible Pathogenic Mechanism of Severe

Thrombotic Complications

An update on the status of COVID-19: a comprehensive review

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

COVID-19, SARS and MERS: A neurological perspective

Infectivity of human coronavirus in the brain

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

Neurologic manifestations of hospitalized patients with Coronavirus disease

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Potential of SARS-CoV-2 to

The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome

Interactions between the microbiota, immune and nervous systems in health and disease

The Brain-Gut-Microbiome Axis

The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of

Alzheimer's Disease-a Critical Review

Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve

A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease

The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue

The Gut Microbiome and Multiple Sclerosis

The role of gut microbiota in immune homeostasis and autoimmunity

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD

SARS-CoV-2 productively infects human gut enterocytes

Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke

Temporal Correlation Between Neurological and Gastrointestinal Symptoms of SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research

Legend of Figure: Figure 1: Communication pathways between the gut -brain. (1) through vagal afferent neurons, (2) through cytokines of the immune system

The authors have no conflict of interest associated with this paper 6